You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Should the dose of Kisunla® (donanemab-azbt) be adjusted for age?
No dosing adjustments are needed for donanemab based on age.
See important safety information, including boxed warning, in the attached prescribing information.
No Dose Adjustment Is Necessary Based on Age
The pharmacokinetics (PK) of donanemab was not affected by age based on a population PK analysis using data collected from 177 participants with Alzheimer's disease aged 54 to 88 years.1,2
In the TRAILBLAZER-ALZ 2 study,3 the age of participants exposed to donanemab ranged from 59 to 86 years, with a mean age of 73 years. Specifically,
- 90% were 65 years and older, and
- 41% were 75 years and older.2
In the TRAILBLAZER-ALZ 6 study,4 the age of participants exposed to donanemab ranged from 59 to 85 years, with a mean age of 74 years. Specifically,
- 93% were 65 years and older, and
- 55% were 75 years and older.2
No overall differences in safety or effectiveness of donanemab have been observed between patients 65 years of age and older and younger adult patients.2
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Gueorguieva I, Willis BA, Chua L, et al. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer’s disease. Clin Pharmacol Ther. 2023;118(36):1258-1267. https://doi.org/10.1002/cpt.2875
2Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
3Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. https://doi.org/10.1001/jama.2023.13239
4Wang H, Nery ESM, Ardayfio P, et al. The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. J Prev Alzheimers Dis. 2025;21(8):100266. https://doi.org/10.1016/j.tjpad.2025.100266
Date of Last Review: May 15, 2026